BVF Inc. IL grew its stake in shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) by 63.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,764,842 shares of the company’s stock after purchasing an additional 3,014,842 shares during the period. Compass Therapeutics makes up about 1.4% of BVF Inc. IL’s holdings, making the stock its 25th largest position. BVF Inc. IL owned about 4.37% of Compass Therapeutics worth $41,697,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the company. Suvretta Capital Management LLC raised its stake in shares of Compass Therapeutics by 97.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 14,101,159 shares of the company’s stock worth $49,354,000 after buying an additional 6,951,666 shares during the last quarter. Vivo Capital LLC raised its stake in shares of Compass Therapeutics by 57.9% during the 3rd quarter. Vivo Capital LLC now owns 9,545,466 shares of the company’s stock worth $33,409,000 after buying an additional 3,502,000 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Compass Therapeutics by 45.6% during the 3rd quarter. Vanguard Group Inc. now owns 7,062,799 shares of the company’s stock worth $24,720,000 after buying an additional 2,212,794 shares during the last quarter. State Street Corp raised its stake in shares of Compass Therapeutics by 57.4% during the 4th quarter. State Street Corp now owns 4,890,525 shares of the company’s stock worth $26,262,000 after buying an additional 1,784,012 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of Compass Therapeutics by 11.3% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 4,424,868 shares of the company’s stock worth $11,505,000 after buying an additional 449,868 shares during the last quarter. Institutional investors and hedge funds own 68.43% of the company’s stock.
Compass Therapeutics Price Performance
NASDAQ CMPX opened at $2.05 on Thursday. Compass Therapeutics, Inc. has a 12 month low of $1.61 and a 12 month high of $6.88. The company has a 50-day moving average of $2.96 and a 200-day moving average of $4.69. The company has a market cap of $369.18 million, a P/E ratio of -5.00 and a beta of 0.89.
Analyst Ratings Changes
Several research analysts have recently issued reports on the company. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 price target on shares of Compass Therapeutics in a research note on Monday, April 27th. HC Wainwright reissued a “buy” rating and issued a $24.00 target price on shares of Compass Therapeutics in a research note on Monday, April 27th. Stifel Nicolaus set a $6.00 target price on shares of Compass Therapeutics in a research note on Monday, June 1st. Wall Street Zen downgraded shares of Compass Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 25th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $9.00 target price on shares of Compass Therapeutics in a research note on Thursday, March 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $12.91.
Compass Therapeutics Profile
Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.
The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.
Featured Articles
- Five stocks we like better than Compass Therapeutics
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
- Critical Metals: Sizing Up This Tiny Rare-Earth Stock Making Big Moves
- Meta and Cloud Computing: Real Potential, or a Shot in the Dark?
Want to see what other hedge funds are holding CMPX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report).
Receive News & Ratings for Compass Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compass Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
